Imugene Limited (AU:IMU) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Imugene Limited, a clinical stage immuno-oncology company, has updated its Appendix 3Z document for Dr. Jens Eckstein. The company is focused on developing innovative immunotherapies to activate the immune system against cancer, with a promising pipeline including CAR T cell therapy and oncolytic virotherapy. Imugene aims to be a leader in the global cancer treatment market, backed by a strong team and robust clinical evidence.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
